A rational utilization of high-throughput screening affords selective, orally bioavailable 1-benzyl-3-carboxyazetidine sphingosine-1-phosphate-1 receptor agonists

J Med Chem. 2004 Dec 30;47(27):6662-5. doi: 10.1021/jm0492507.

Abstract

Moderately potent, selective S1P(1) receptor agonists identified from high-throughput screening have been adapted into lipophilic tails for a class of orally bioavailable amino acid-based S1P(1) agonists represented by 7. Many of the new compounds are potent S1P(1) agonists that select against the S1P(2), S1P(3), and S1P(4) (although not S1P(5)) receptor subtypes. Analogues 18 and 24 are highly orally bioavailable and possess excellent pharmacokinetic profiles in the rat, dog, and rhesus monkey.

MeSH terms

  • Administration, Oral
  • Animals
  • Azetidines / pharmacokinetics
  • Azetidines / pharmacology*
  • Biological Availability
  • CHO Cells
  • Cricetinae
  • Dogs
  • Drug Design
  • Guanosine 5'-O-(3-Thiotriphosphate) / metabolism
  • Humans
  • Immunosuppressive Agents / pharmacokinetics
  • Immunosuppressive Agents / pharmacology*
  • Lymphocytes / drug effects
  • Macaca mulatta
  • Mice
  • Rats
  • Rats, Inbred Lew
  • Receptors, Lysosphingolipid / agonists*
  • Structure-Activity Relationship

Substances

  • Azetidines
  • Immunosuppressive Agents
  • Receptors, Lysosphingolipid
  • Guanosine 5'-O-(3-Thiotriphosphate)